Proactive Investors - Run By Investors For Investors

Sienna Cancer Diagnostics to launch its in-vitro test in Denmark and Sweden

New distribution agreement to accelerate the global roll out of Sienna’s hTERT IVD test.
Cancer header on a newspaper
Sienna's test help urologists detect bladder cancer

Sienna Cancer Diagnostics Ltd (ASX:SDX) has appointed Axlab A/S as the exclusive distribution partner for its in-vitro diagnostic (IVD) tests in Denmark and Sweden.

The Australia based Sienna’s hTERT test help urologists to detect bladder cancer earlier, and thereby improve patient welfare and lower overall costs in the healthcare system.

This new distribution agreement will broaden and accelerate the global roll out of Sienna’s hTERT IVD test.

Additionally, the agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories.

Axlab is a Denmark based experienced supplier of instruments, reagents and consumables for histology and cytology.

Sienna plans to penetrate its products into the Nordic market using Axlab’s existing facilities and significant knowledge in cytology.

Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.

The regulation of telomerase activity in human cells plays a significant role in the development of cancer.

Importantly, clinical pathology laboratories in the region may now purchase Sienna’s IVD product to detect the presence of hTERT, a component of telomerase.

View full SDX profile View Profile

Sienna Cancer Diagnostics Ltd Timeline

Related Articles

cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago
researcher at microscope
May 25 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use